Abstract-Objective: To describe the incidence and nature of neurologic complications following liver transplantation. Methods: Adult patients who received liver transplants at St. James's University Hospital between September 1, 1990, and August 31, 2000, were identified. Case notes were reviewed and demographic data, details of the liver disease, neurologic complications, and discharge information were recorded. Results: The authors identified 657 patients and traced the case notes of 627 (95.4%). These patients had a total of 711 transplants. Neurologic complications occurred following 185 transplants (26%) affecting 170 patients (27%). The most common complications were diffuse encephalopathies, which affected 66 patients (11%), and seizures, which affected 37 patients (6%). Forty-three percent of patients with alcoholic liver disease and 41% of patients with primary biliary cirrhosis experienced a neurologic complication. These proportions were higher than for other transplant indications (p Ͻ 0.001). Patients who experienced a neurologic problem spent longer in hospital (p Ͻ 0.01) and had a poorer outcome (p Ͻ 0.001). Conclusions: Neurologic complications occur following 26% of liver transplants. A higher proportion of patients who received transplants for alcoholic liver disease and primary biliary cirrhosis experienced neurologic complications than those receiving transplants for other reasons. Patients who experience a neurologic problem spend longer in hospital and have a poorer outcome.
Since its introduction in the 1960s, liver transplantation has revolutionized the management of patients with end-stage liver failure. Initially it was considered a high-risk procedure and only about 20% of patients survived, with graft rejection being the most common reason for transplant failure. 1 This changed little over the next decade until the introduction of cyclosporine in the late 1970s, which resulted in a dramatic improvement in prognosis, with centers reporting over 80% survival rates. 1 Since then, liver transplantation has been performed with increasing frequency and remains at the very edge of medical and surgical technology.
Between 600 and 700 liver transplants are performed in the United Kingdom each year with the major limiting factor being donor organ availability. 2 St. James's University Hospital has performed nearly 1,000 liver transplants in more than 900 patients since the Liver Transplant Unit opened in 1988. It is one of only seven centers in the United Kingdom and provides a liver transplant service for a population of over 10 million, covering Yorkshire, the M62 corridor, and Northern Ireland, as well as accepting patients from further afield.
Many complications can occur after liver transplantation. Problems related to the functioning of the nervous system make up one of the largest groups and have a major impact on survival, disability, and quality of life. Affected patients spend more days in hospital, the total cost of their care is greater, and they require greater input after discharge. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In the study by Pujol et al., 55% of patients with neurologic complications died, compared to 17% of those without. 8 However, there have been few major studies in this area, with the largest series to date consisting of 273 adult patients from a total series of 391. 13 This article was a retrospective report of the experience of a single center in the United States over a 5-year period. They report neurologic complications of various types occurring in 23% of patients.
In the United Kingdom, there have been little data reported, with only a single retrospective study of any size being published. 3 This article looked at 52 patients who received transplants at the Queen Elizabeth Hospital in Birmingham between 1982 and 1986. Unfortunately, the authors included 10 children in the series, making it difficult to generalize from their findings. Children tend to have different indications for liver transplantation and a different spectrum of complications. 2, 13, 14 The Birmingham study and others from abroad have suggested that neurologic complications occur in about 30% of patients and that these patients have a higher mortality and morbidity. 3, 4, [6] [7] [8] [9] [10] [11] 13, [15] [16] [17] Although the overall survival of these patients posttransplant has improved dramatically over the years with the introduction of new surgical, medical, and, in particular, immunosuppressive techniques, there has been little change in the incidence of neurologic complications. In 1978, a study found neurologic complications in 19% of patients, 16 and 9 years later, in 1987, this figure was 33% of patients. 3 Over subsequent years other studies have found little change in this figure, which remains around 30%. [6] [7] [8] [9] 11, 13, 15, [17] [18] [19] [20] [21] [22] Although it is likely that patient selection for liver transplantation and perioperative care has changed over this period, it is of concern that despite the decline in the overall mortality of the procedure, the incidence of neurologic complications has remained static.
In this report, we describe the incidence of major neurologic complications occurring in hospital following liver transplantation, relate their occurrence to the primary liver disease or to the primary immunosuppressant, and assess their impact on length of hospital stay and outcome.
Methods. We identified all adult (over 18 years of age) patients who had undergone liver transplantation at St. James's University Hospital between September 1, 1990, and August 31, 2000, using the Leeds transplant database. During this period patients were cared for by medical hepatologists, transplant surgeons, and transplant anesthetists. All operative procedures were performed using standard techniques including veno-venous bypass and postoperative care was similar for all patients. All immunosuppressant regimens were based around oral calcineurin inhibitors.
The case notes were reviewed by M.B.L. and the following data were collected: sex, age at transplantation, indication for transplantation, secondary diagnoses, primary immunosuppressant, occurrence and nature of neurologic complications, length of stay post-transplant, place of discharge, and outcome.
Outcome was assessed using a modified version of the original Glasgow Outcome Scale 23 (GOS; see table 1) , with a GOS of 5 being a good outcome and a GOS of 1 through 4 being a poor outcome (death is represented by a GOS of 1). Postmortem reports were reviewed where available.
The patients were grouped according to the presence (Group 1) or absence (Group 2) of neurologic complications.
Statistical analysis was performed using the Mann-Whitney U test to compare lengths of stay and Fisher exact or 2 test to compare the proportions from each group who died, had complications, and were not discharged directly home.
Results. We identified 657 adult patients who had received transplants between September 1, 1990, and August 31, 2000. Thirty patient records (4.6%) could not be traced, leaving 627 available for study. Of the remaining 627 patients, there were 376 men (60%) and 251 women (40%). During the study period, these patients underwent 711 transplants; 59 patients had two transplants, 11 patients had three transplants, and 1 patient had four transplants. Median age at transplantation was 49 years (interquartile range [IQR] 38 to 56 years), with a mean of 46.92 years (SD 12.39).
The primary liver diagnoses are summarized in table 2. The miscellaneous group includes vascular causes (n ϭ 15), secondary biliary cirrhosis (n ϭ 10), hemochromatosis (n ϭ 9), Wilson disease (n ϭ 3), alpha-1-antitrypsin deficiency (n ϭ 3), polycystic disease (n ϭ 3), sarcoidosis (n ϭ 3), amyloidosis (n ϭ 3), congenital liver disease (n ϭ 2), cystic fibrosis (n ϭ 2), biliary cyst (n ϭ 1), Coroli syndrome (n ϭ 1), Castleman syndrome (n ϭ 1), and tuberculosis (n ϭ 1).
The malignancy group includes cholangiocarcinomas (n ϭ 10), liver metastases (n ϭ 9), neuroendocrine tumors (n ϭ 7), and primary hepatocellular carcinomas (n ϭ 3).
The acute liver failure group includes fulminant viral hepatitis (n ϭ 32), paracetamol overdose (n ϭ 27), other drug or toxin (n ϭ 13), vascular (n ϭ 2), and unknown (n ϭ 3).
Many patients had more than one liver diagnosis (table 3) . Neurologic complications occurred following 185 transplant operations, giving an incidence in our population of 26%. These complications affected 170 patients (27%): 100 men (59%) and 70 women (41%). These patients constitute Group 1. The remaining 457 patients constitute Group 2.
There were 402 patients whose immunosuppressant regimen was based around cyclosporine and 156 whose regimen was based around tacrolimus. There were no significant differences between these two groups in any of the areas studied (table 4) .
In 35 patients, no immunosuppressant regimen was established owing to the severity of their initial illness or postoperative complications, or both. All of these patients subsequently died at a median of 16 days (range 1 to 52).
In the remaining 34 patients, other regimens were used or it was not clear from the notes which drugs the patient was taking. CNS complications. The most common complication was a diffuse encephalopathy, which occurred following 70 transplants (10%) in 66 patients (11%). Seizures occurred following 43 transplants (6%) in 37 patients (6%); 13 of the 66 patients with encephalopathy had accompanying seizures.
Cerebrovascular complications occurred following 24 transplants (3%) affecting 24 patients (4%): 12 had cerebral infarcts, 10 had intracerebral hemorrhages, and 2 had subarachnoid hemorrhages.
Headaches occurred in 30 patients (5%) and new persistent tremor occurred in 17 patients (3%). There were 11 cases of central pontine myelinolysis (2%). Six patients (1%) developed the reversible posterior leukoencephalopathy syndrome.
There were also five cases of myoclonus, three cases of sensorineural hearing loss, three cases of viral encephalitis, two cases of bacterial meningitis, one case of tuberculous meningitis, and one case of fungal meningitis.
Neuromuscular complications. Twenty-seven patients (4%) developed neuromuscular complications: 12 mononeuropathies, 6 acute myopathies, 6 brachial plexopathies, and 3 new peripheral neuropathies.
Length of stay. Excluding deaths, the overall median length of stay was 17 days (IQR 12 to 26 days). For Group 1, this was 19.5 days (range 12.5 to 30.5 days), compared with 16 days (IQR 12 to 22.5) for Group 2 (p ϭ 0.0048).
Overall, 69 patients (11%) had to be transferred to other institutions for continuing care. Within Group 1, 47 patients (28%) were transferred to another institution rather than being discharged directly home. This compares with only 22 patients (5%) from Group 2 (p Ͻ 0.0001).
Outcome. Forty-five patients (7%) died: 20 (12%) in Group 1, and 25 (5%) in Group 2 (p ϭ 0.009). In those who survived, neurologic complications were associated with increased morbidity. Forty-two patients (28%) from Group 1 had a significant disability at discharge (GOS of 2 to 4), compared to 15 patients (4%) from Group 2 (p Ͻ 0.0001).
Overall, 102 patients (16%) had a poor outcome (GOS 1 to 4): 36% (n ϭ 62) of Group 1 and only 9% (n ϭ 40) of Group 2 (p Ͻ 0.0001).
Some of the above results are summarized for each of the main liver diagnoses in table 5 . This reveals that neurologic complications occur in higher proportions of patients who receive transplants for alcoholic liver disease (43%, p Ͻ 0.0001) and primary biliary cirrhosis (41%, p ϭ 0.0008) than for other indications.
Discussion. Neurologic complications are common following liver transplantation, are associated with significant mortality and morbidity, and lead to patients remaining longer in hospital.
We have shown that major neurologic complications occur following 26% of Liver transplants at St. James's University Hospital. The incidence and nature of the neurologic complications in the St. James's liver transplant population are in line with the results from other centers both in the United Kingdom and abroad. Most studies have found that neurologic complications occur in about 30% of cases and it is of concern that over the years their incidence has not fallen. 17 We were unable to detect any differences in the incidence of neurologic complications, or in any of the other variables studied, related to the primary immunosuppressant used. There do, however, appear to be differences in the incidence of complications in the different etiologies of liver disease. Over 40% of patients with alcoholic liver disease experienced neurologic complications. In addition, patients with primary biliary cirrhosis had a higher rate of neurologic complications although this might be due to the disease affecting an older population. It is always difficult to draw conclusions from retrospective data, and for this reason we have not set out to establish specific risk factors, but rather to highlight areas for potential future prospective studies. CNS complications. A diffuse encephalopathy is the most common complication following liver transplantation, 3,7,10 which was confirmed in our study (11% of Hepatitis B (2) Hemochromatosis (1) Primary biliary cirrhosis (99) Overlap syndrome (1) CREST syndrome (1) Hepatitis C (85) Hepatocellular carcinoma (10) HIV and hemophilia (1) Hepatitis B (2) Hemophilia (1) Schistosomiasis (1) Hepatitis B (38) Hepatocellular carcinoma (1) Autoimmune hepatitis (25) Hepatocellular carcinoma (1) CREST ϭ calcinosis, Raynaud disease, esophageal dysmotility, and telangiectasia. IQR ϭ interquartile range. patients). The mechanisms underlying this are unknown, although in a large prospective study the authors diagnosed a diffuse encephalopathy (anoxic, septic, or metabolic) as being the most common complication, occurring in 13 (15%) of 84 patients, 8 and postmortem studies show diffuse anoxic-ischemic changes as the most common neuropathologic finding. 24, 25 Seizures are common following liver transplantation, although the range of reported incidences is wide, varying from 0% to over 40% and higher in some small series with large numbers of repeat transplants. 3, 8, 10, 13, 17, 26 In our study, 6% of patients experienced seizures and the incidence of seizures after liver transplant appears to be declining. One group that initially reported relatively high seizure rates in their initial study saw a reduction in seizure incidence in patients treated more recently (from 42% to 0%). 9, 17 The reasons for this are unclear, although it is likely to represent improvements in the management of the multiple metabolic and toxic abnormalities that may predispose to this complication.
The reversible posterior leukoencephalopathy syndrome consists of headache, visual disturbance, and seizures, which can be caused by a variety of conditions and immunosuppressants. [27] [28] [29] [30] It is apparent from the literature that this syndrome has been occurring for some time in post-liver transplant patients but has been reported under several different names. The current term is in itself misleading because the condition is not always reversible, nor is it always restricted to posterior structures or white matter. The true incidence of this encephalopathy is difficult to establish but it appears to occur to some extent in about 5% of patients. 3, 7, 9, 10, 17, 26, [31] [32] [33] [34] [35] [36] In our study we only identified it in 1% of cases, possibly as a result of our retrospective design. A prospective study involving neuroimaging and assessment by a neurologist post-transplant would be needed to establish the true incidence of this complication.
Our findings of central pontine myelinolysis occurring in 2% of cases is in line with other centers. 3 This complication is likely to be underestimated in a retrospective study and postmortem data show that subclinical central pontine myelinolysis is probably more common. 37 Infections of the CNS tend to occur relatively early post-transplant 1, 4 and have been well reported in previous studies. 3, 6, 8, 13, 17, 24, 26 About 5% of patients will be affected at some point following their transplantation with the most likely organism depending on the time since transplantation. In our study 1% of patients experienced a CNS infection during their inpatient period, which is in keeping with the results from other centers.
Cerebrovascular complications occur in about 4% of cases in clinical series, 3, 7, 8, 13 which was also our finding. They can, however, be detected in about 40% of cases in autopsy series. 38, 39 Headaches and tremor are very common complaints among patients taking immunosuppressants such as cyclosporine and tacrolimus, 40 but they are mentioned in only a few studies as being a neurologic complication. 9, 13 The incidence of these and other relatively minor complications is always likely to be underestimated in a retrospective study, which relies on documentation in patients' notes. There appears to be a tendency to blame the immunosuppressant being used for these minor problems, although, particularly as far as headaches are concerned, a multifactorial cause in many cases would seem more likely. 4 Profound sensorineural hearing loss occurred in three of our patients (0.5%). This has not been reported previously in adult liver transplantation. Deafness has occurred in pediatric patients undergoing liver transplantation 41 and has previously been reported in association with both tacrolimus and cyclosporine, 42, 43 although both cases were in renal transplant recipients. With our retrospective study design, it is difficult to know why these patients developed this complication. We suspect that the etiology was multifactorial, with fluid shifts and metabolic and toxic abnormalities as well as drugs all playing a role, although the commonly recognized ototoxic drugs were not a factor.
Neuromuscular complications. Neuromuscular complications following liver transplantation are less common than CNS problems. In our study they affected 4% of patients, which is in line with previous studies. Peripheral nerves and muscles are most commonly affected, although plexus lesions and neuromuscular junction problems can occur. 44 Many peripheral nerve and plexus injuries have been described 44 but the most common are probably ulnar nerve and brachial plexus lesions, which occur in about 2 to 4% of cases. 9, 13, 45, 46 The mechanism of these palsies is largely explained by the prolonged anesthetic time, both intraoperatively and in the intensive care unit, the need for invasive monitoring and access, and pretransplant factors such as alcoholism and nutritional deficiencies. [7] [8] [9] 13, 45, 47, 48 A more specific cause of mononeuropathies in these patients is the coagulopathy that many experience and this may predispose to hemorrhagic nerve compression. 45 Myopathy has been described previously and a large prospective series suggested an incidence of about 7%. 47 Although there were some problems with follow-up and investigation of cases in the study, it is the largest prospective series to date. The etiology of myopathy following liver transplantation is multifactorial. Prolonged use of and persistence of neuromuscular blocking agents and their metabolites is suggested as one contributory factor; IV high-dose corticosteroids may also play a role, as may cyclosporine and tacrolimus. 47, 48 Most of these complications are not unique to liver transplantation and occur in similar surgical and nonsurgical critically ill patients. 44 
